Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and bay 1000394

sorafenib has been researched along with bay 1000394 in 2 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(bay 1000394)		Trials
(bay 1000394)		Recent Studies (post-2010) (bay 1000394)
6,5207305,25119219

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)bay 1000394 (IC50)
NUAK family SNF1-like kinase 1Homo sapiens (human)0.01
Cyclin-T1Homo sapiens (human)0.005
Cyclin-dependent kinase 1Homo sapiens (human)0.0067
Cyclin-dependent kinase 4Homo sapiens (human)0.0101
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.007
G1/S-specific cyclin-D1Homo sapiens (human)0.011
G1/S-specific cyclin-E1Homo sapiens (human)0.0092
Cyclin-dependent kinase 2Homo sapiens (human)0.0086
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.163
Cyclin-dependent kinase 7Homo sapiens (human)0.021
Cyclin-dependent kinase 9Homo sapiens (human)0.005
Cyclin-HHomo sapiens (human)0.025
CDK-activating kinase assembly factor MAT1Homo sapiens (human)0.025
Cyclin-dependent kinase 3Homo sapiens (human)0.007
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.01
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.01

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, W; Kan, Q; Li, Y; Tian, X; Wang, S; Wei, H; Yang, Z1
Chou, TC; Hsueh, C; Lin, JD; Lin, SF; Wong, RJ1

Reviews

1 review(s) available for sorafenib and bay 1000394

ArticleYear
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
    European journal of medicinal chemistry, 2019, Feb-15, Volume: 164

    Topics: Animals; Crystallography, X-Ray; Cyclin-Dependent Kinases; Humans; Molecular Structure; Protein Binding; Protein Kinase Inhibitors

2019

Other Studies

1 other study(ies) available for sorafenib and bay 1000394

ArticleYear
Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer.
    Endocrine-related cancer, 2018, Volume: 25, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Phosphorylation; Pyrimidines; Signal Transduction; Sorafenib; Sulfoxides; Thyroid Neoplasms

2018